Important limitations
- Individual claims and source links have not yet completed editorial verification.
- Evidence level, applicable study model, formulation, route and population remain unassigned.
Vesilute
Vesilute is a bioregulator peptide targeting the urinary tract and prostate gland.
Dosing & scaling, explained
The moderated mass amounts below are retained for comparison. Near-duplicates, mix-dependent volumes and device markings are excluded. This is educational source context, not a protocol or recommendation.
Mass amounts available for comparison
- Lower range1 mgDose
Recorded example with no verified study backing; shown for amount literacy only.
- Mid range5 mgDose
Recorded example with no verified study backing; shown for amount literacy only.
Only mcg or mg amounts are retained. The calculator derives mL, syringe units or pen clicks from the current vial strength, water volume and device.
No independently verified schedule
Evidence context
No clinical amount or schedule is inferred from this material. Source verification is pending, and every displayed amount remains educational context rather than guidance.
Storage, handling and interpretation
Product identity
Verify the exact compound, formulation and amount against the product label or certificate before calculation.
Storage & handling
Follow the product label, certificate and validated laboratory SOP; no universal storage assumption is applied here.
Prepared solutions
Label concentration and preparation date, use sterile technique where applicable, and follow a validated stability protocol.
Reported protocols for Vesilute
What published studies and recent community write-ups report about amounts, timing and course length. 2 community-reported rows, each linked to its source. These are descriptions of what others report, not instructions, and nothing here is medical advice.
| Context | Dose | Frequency | Route | Course | Source |
|---|---|---|---|---|---|
| Community-reported2 rows | |||||
| Capsule or vial course in the Khavinson pattern | 1-2 Cytomed capsules per day, or 1-2 mg subcutaneously (5 mg vial in 2.5 mL gives 2 mg/mL) | Once daily | Oral capsules swallowed before breakfast, or subcutaneous injection from a reconstituted vial | About 10 days for the vial pattern; 10-30 days for capsulesRepeated once or twice a year | Community resource2026 |
| A calculator site's August 2026 page lists Vesilut as the bladder cytogen that most Western catalogs omit and flags that English sequence tables disagree, calling Glu-Asp catalog-common and telling readers to rely on HPLC. It rates the evidence as low, says the course pattern is the school's convention rather than a tested schedule, and warns that name confusion with Vesugen leads to the wrong vials being shipped. | |||||
| Manufacturer-style capsule schedule | 1-2 capsules of 0.2 g (labelled as containing the AKS-M peptide complex) | 1-2 times daily with meals | Oral capsules; research vials (10 mg in 2 mL bacteriostatic water) described as subcutaneous or intramuscular | 20-30 days per courseRepeat every 4-6 months | Community resource2026 |
| This technical page reproduces the Russian capsule leaflet pattern of 20 to 30 day courses several months apart and states that outside Russia the peptide has no approval or recognized indication. It lists only injection-site pain and rare redness as side effects and gives a half-life of 2 to 4 hours without a citation, which is longer than would be expected for a dipeptide. | |||||
How a course is commonly described
- Days 1-10: courseCommunity-reported
The vial pattern is a short daily pulse of about 1-2 mg subcutaneously for roughly 10 days. No source describes what, if anything, is expected to change during the course, and no study has measured anything.
- Days 1-30: capsule courseCommunity-reported
Capsule courses run 20 to 30 days at one to two capsules once or twice a day with meals. The capsules are a Russian supplement product and are not the same thing as the research vial.
- Break: 4-6 monthsCommunity-reported
Courses are repeated every 4 to 6 months, or once or twice a year, with nothing taken in between. This is the generic Khavinson cycling pattern applied to every peptide in the line rather than anything measured for Vesilute.
- There is no published study of Vesilute in people or animals, so no dose, course length or break has any evidence behind it. The rows above record vendor and manufacturer conventions only.
- The sequence itself is disputed between vendors (Glu-Asp versus Lys-Glu-Asp), and one vendor publishes no sequence at all for that reason. A certificate of analysis is the only way to know what a given vial contains.
- Vesilute is not approved anywhere. Bladder and prostate symptoms have established medical treatments, and nothing here is a recommendation.
Sources for this section (4)
Plus 4 community resources (dosing guides, forum threads and vendor write-ups), reported above but not linked.
Overview
Vesilute (also written Vesilut, from the Latin vesica for bladder) is the urinary bladder entry in the Cytomed and NPCRIZ line of synthetic short peptides that grew out of Vladimir Khavinson's bioregulator program in St. Petersburg. Most English catalogs give its sequence as the dipeptide Glu-Asp (ED), which is the record shown here; some vendors list the tripeptide Lys-Glu-Asp, which is Vesugen, and at least one vendor declines to publish any sequence because the sources disagree, so the identity of a given vial rests on its certificate of analysis. No peer-reviewed clinical or animal study of Vesilute itself is indexed in PubMed, and the bladder, prostate and fertility claims attached to it are extrapolated from the wider Khavinson short-peptide literature and from vendor copy. It is sold in Russia as a capsule supplement and elsewhere as 10-20 mg research vials, has no regulatory approval anywhere, and the protocol rows below are therefore all community descriptions of the generic Khavinson cycling pattern.
What researchers are exploring
These themes organize the educational information currently available. Individual claims remain under source review and are not treatment claims.
- 1
Research on Vesilute
Vesilute and other cytomedines also appear to have positive effects on sperm quality and fertility. Research conducted in Russia indicates that the administration of cytomedines can lead to increased sperm production,…
What is known and what still needs verification
Available context is organized without assigning unsupported study models or evidence grades.
- Not graded
Research on Vesilute
Vesilute and other cytomedines also appear to have positive effects on sperm quality and fertility. Research conducted in Russia indicates that the administration of cytomedines can lead to increased sperm production, improved sperm health, and higher…
Amounts recorded for Vesilute
These amount records are independent from vial strength, reconstitution volume and measuring device. A recorded source is not the same as study backing, and these values are not recommendations.
- 1Dose · lower endpointSign in for schedule, duration and source context.1 mg
- 2Dose · upper endpointSign in for schedule, duration and source context.5 mg
Chemistry identifiers
Sequence, synonyms and registry identifiers as recorded in PubChem, the National Library of Medicine's open chemistry database. Formula, mass and CAS number are summarized at the top of the page.
Sequence
Glu-Asp
Also listed as
Glu-Asp, ED dipeptide, alpha-Glutamylaspartic acid, H-Glu-Asp-OH, L-alpha-Glutamyl-L-aspartic acid, UNII 38Y324JU2X, CHEBI:73503, NSC 186905
InChIKey
FYYSIASRLDJUNP-WHFBIAKZSA-N
IUPAC name
(2S)-2-[[(2S)-2-amino-4-carboxybutanoyl]amino]butanedioic acid
Limitations and unknowns
Sources
1 link carried over from the earlier page, awaiting verification.